Controlled Release Pharmaceuticals: Liposomal Formulation

Liposomal Amphotericin B (LAmB-S) in Saline Suspension was a critical unmet medical need and a life-saving drug used for treatment of Kala-azar (Visceral Leishmaniasis; VL) and systemic fungal infections. Healthcare products developed using Liposomal Technology were entirely new to the world at that time. India was solely dependent on imported Liposomal Amphotericin B resulting in outgo of precious foreign exchange. FUNGISOME is both an import substitute and source of export income. FUNGISOME i.v. is the first in Asia and one of the only two Liposomal Amphotericin B injections in the world and is produced by M/s Lifecare Innovations Private Limited. It is the only hepato-safe and nephro-safe antifungal drug. The Nephrotoxicity, anti-fungal efficacy and daily dose of FUNGISOME are zero, >90%, 1-3mg/kg body wt./day in comparison to the imported LAmB which is 27%, 50% and 3-6mg/kg/day respectively, making FUNGISOME safer, more effective, and an economical drug to treat systemic fungal infections. FUNGISOME is effective in the treatment of MDR nosocomial infections viz. Candida auris, and Candida haemuloni that are resistant to imported LAmB. FUNGISOME has helped hospitals minimize mortality and morbidity caused by fungal infections and antifungal drugs.